Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Pyridostigmine inhibits acetylcholinesterase, preventing the breakdown of acetylcholine at neuromuscular junctions and autonomic ganglia. Increased acetylcholine improves neuromuscular transmission in myasthenia gravis and enhances ganglionic autonomic signaling in dysautonomia.
Commercial pyridostigmine (Mestinon) is only available at 60mg tablets — too high for many POTS patients who require 30mg or lower starting doses. Compounded liquid formulations and custom doses allow precise titration and pediatric dosing.
Compare up to 7,500 pharmacies across the USA.
Pyridostigmine was originally developed for myasthenia gravis, where it improves neuromuscular transmission by preventing acetylcholine breakdown. In the past decade, research has demonstrated its effectiveness for hyperadrenergic POTS by enhancing ganglionic neurotransmission and reducing sympathetic nervous system overactivation.
POTS patients often require doses well below the commercial 60mg tablet, making compounded lower-dose capsules and liquid formulations essential. Custom pyridostigmine also benefits MCAS and dysautonomia patients who react to commercial Mestinon fillers and coatings.
Acetylcholinesterase Inhibition
Pyridostigmine reversibly inhibits acetylcholinesterase at cholinergic synapses, preventing the breakdown of acetylcholine. This increases acetylcholine concentration and duration of action at neuromuscular junctions and autonomic ganglia.
Ganglionic Neurotransmission Enhancement (POTS)
In dysautonomia, enhanced ganglionic acetylcholine signaling improves parasympathetic outflow and normalizes the sympathovagal balance. This reduces the excessive sympathetic activation that drives heart rate elevation and adrenergic symptoms in hyperadrenergic POTS.
Neuromuscular Junction Improvement (Myasthenia Gravis)
In myasthenia gravis, autoantibodies destroy nicotinic acetylcholine receptors at neuromuscular junctions. By preserving acetylcholine from breakdown, pyridostigmine compensates for reduced receptor density, improving muscle strength and endurance.
Myasthenia gravis, POTS (postural orthostatic tachycardia syndrome), dysautonomia, hyperadrenergic POTS, orthostatic hypotension, autonomic neuropathy, post-COVID dysautonomia, Ehlers-Danlos syndrome with dysautonomia
Postoperative urinary retention and ileus (cholinergic stimulation), reversal of non-depolarizing neuromuscular blockade (anesthesia recovery), orthostatic hypotension adjunct, Gulf War illness symptom management (investigational), congenital myasthenic syndromes
Myasthenia gravis: 60mg every 3–4 hours (standard Mestinon dosing)
POTS starting dose: 30mg once or twice daily
POTS therapeutic range: 30–60mg 2–3x daily, titrated to orthostatic response
Pediatric: Weight-based dosing requires compounded liquid formulation
POTS: Start 30mg once daily with a meal; increase to 30mg BID after 1 week if tolerated; advance to 30–60mg TID per orthostatic response. Take doses timed 30–60 minutes before activities requiring standing or exertion.
Myasthenia gravis: Prescriber-directed titration based on muscle strength response; typically 60mg every 3–4 hours initially.
GI side effects: Always take with food to reduce nausea, cramping, and diarrhea. Start low and increase slowly.
Compounded Capsules (10mg, 30mg) — low-dose options unavailable commercially; essential for POTS titration and sensitive patients
Dye-free 60mg Capsules — equivalent to commercial Mestinon 60mg but without dyes and problematic excipients for MCAS patients
Oral Liquid Suspension — typically 12mg/mL for pediatric dosing or patients requiring very precise low-dose titration
GI symptoms (nausea, abdominal cramping, diarrhea) — take with food to reduce. Increased sweating and salivation (cholinergic effects). Muscle twitching at higher doses. Take smallest effective dose to minimize cholinergic side effects.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
